Will Avilamycin Convert Ziracine into Zerocine?
Open Access
- 1 October 2000
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 6 (5) , 558
- https://doi.org/10.3201/eid0605.000521
Abstract
Volume 24, Number 10—October 2018 - Emerging Infectious Diseases journal - CDCKeywords
This publication has 7 references indexed in Scilit:
- Evernimicin (SCH27899) Inhibits a Novel Ribosome Target Site: Analysis of 23S Ribosomal DNA MutantsAntimicrobial Agents and Chemotherapy, 2000
- Evernimicin Binds Exclusively to the 50S Ribosomal Subunit and Inhibits Translation in Cell-Free Systems Derived from both Gram-Positive and Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2000
- Mutations in Ribosomal Protein L16 Conferring Reduced Susceptibility to Evernimicin (SCH27899): Implications for Mechanism of ActionAntimicrobial Agents and Chemotherapy, 2000
- Use of Antimicrobial Growth Promoters in Food Animals and Enterococcus faecium Resistance to Therapeutic Antimicrobial Drugs in EuropeEmerging Infectious Diseases, 1999
- Transmission of VanA-Type Vancomycin-Resistant Enterococci andvanAResistance Elements between Chicken and Humans at Avoparcin-Exposed FarmsMicrobial Drug Resistance, 1998
- Association Between Decreased Susceptibility to a New Antibiotic for Treatment of Human Diseases, Everninomicin (SCH 27899), and Resistance to an Antibiotic Used for Growth Promotion in Animals, AvilamycinMicrobial Drug Resistance, 1998
- Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive SpectrumClinical Microbiology & Infection, 1995